CRISPR Shareholders Equity Trend from 2010 to 2022

CRSP
 Stock
  

USD 60.77  2.23  3.54%   

CRISPR Therapeutics Shareholders Equity yearly trend continues to be very stable with very little volatility. Shareholders Equity is likely to grow to about 2.6 B this year. During the period from 2010 to 2022, CRISPR Therapeutics Shareholders Equity quarterly data regression pattern had range of 2,617,988,053 and median of  187,832,000. CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 30th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
  
Refresh
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement various CRISPR Therapeutics Technical models. Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Therapeutics Quarterly Shareholders Equity

2.24 Billion

Share

CRISPR Shareholders Equity Breakdown

Showing smoothed Shareholders Equity of CRISPR Therapeutics AG with missing and latest data points interpolated. A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.CRISPR Therapeutics' Shareholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CRISPR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Shareholders Equity10 Years Trend
Increasing
Slightly volatile
 Shareholders Equity 
Share
      Timeline 

CRISPR Shareholders Equity Regression Statistics

Arithmetic Mean 641,553,927
Geometric Mean 99,065,247
Coefficient Of Variation 149.27
Mean Deviation 773,199,130
Median 187,832,000
Standard Deviation 957,674,506
Range 2,617,988,053
R-Value 0.85
R-Squared 0.73
Significance 0.00021446
Slope 209,612,727

CRISPR Shareholders Equity History

2015-29.1 M
2016232.8 M
2017187.8 M
2018392.2 M
2019939.4 M
20201.7 B
20212.4 B
20222.6 B

Other Fundumenentals of CRISPR Therapeutics

CRISPR Therapeutics Shareholders Equity component correlations

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's Shareholders Equity, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Shareholders Equity2.4 B2.6 B
Average Equity2.3 B2.5 B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.